Table 2. Prevalence of transmitted HIV drug resistance according to the SDRM mutation list and of acquired HIV drug resistance according to the IAS mutation list.

Transmitted HIV drug resistance	n (%)	(95% CI)	Beta	OR (95% CI)	p for trend
First Prot/RT sequence from naive patients	Prevalence of DRMs according to SDRM mutation list (Bennett D. et al. 2009)
Total	1950 (100.0%)				p (2001–2011)
DRMs	203 (10.4%)	(9.1–11.8)	−0.018	0.98 (0.92–1.04)	0.561
NRTI mutations	128 (6.6%)	(5.5–7.8)	−0.016	0.98 (0.91–1.06)	0.667
TA mutations	89 (4.6%)	(3.7–5.6)	0.002	1.00 (0.92–1.10)	0.972
T215revertants	56 (2.9%)	(2.2–3.7)	0.058	1.06 (0.94–1.19)	0.337
NNRTI resistance	61 (3.1%)	(2.4–4.0)	−0.031	0.97 (0.87–1.08)	0.560
PI resistance	56 (2.9%)	(2.2–3.7)	−0.020	0.98 (0.88–1.10)	0.723
Single/multi drug class resistance	203 (10.4%)
One class resistance	169 (8.7%)	(7.5–10.0)
Two classes resistance	26 (1.3%)	(0.9–1.9)
Three classes resistance	8 (0.4%)	(0.2–0.8)

Highly significant results are marked in bold fonts.